Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

MYM. Y. YuHXHuijun XuJCJiazhen Cui

Discussion

Loading...

Member takes

Overview

Phase 1 study shows safety of CD7 CAR T-cell therapy and haploidentical HSCT in hematologic malignancies, implying potential for improved outcomes.

Key Points

  • To evaluate the safety and clinical outcomes of sequential CD7 CAR T-cell therapy followed by haploidentical HSCT without GVHD prophylaxis.
  • Phase 1, single-arm study
  • Eligible patients with relapsed/refractory CD7-positive hematologic malignancies
  • Lymphodepleting chemotherapy followed by infusion of CD7 CAR T cells
  • Haplo-HSCT performed post complete remission with incomplete hematologic recovery
  • 84.2% experienced cytokine release syndrome, mostly at grades 1-2
  • 100% of patients reported grades 3-4 cytopenia
  • 47.4% experienced acute GvHD post-HSCT
  • 94.1% achieved full donor chimerism at 1 month post-transplantation
  • OS and PFS rates at 12 months were 54.8% and 48.7%, respectively

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d47ahttps://doi.org/10.1182/blood-2025-1040
View Full Paper
Ask AI
Bookmark
Share